Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: A case report

Cases Journal

Volumn 2, Issue 12, 2009, Pages

  Valsuani, Chiara ^a   Siclari, Olimpia ^a   Camerini, Andrea ^a   Canale, Maria Laura ^b   Rondini, Marianna ^a   Donati, Sara ^a   Puccinelli, Paolo ^a   Tartarelli, Gianna ^a   Puccetti, Cheti ^a   Amoroso, Domenico ^a  

^a Versilia Hospital   (Italy)

^b Ospedale San Sebastiano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; BISOPROLOL; FUROSEMIDE; RAMIPRIL; SORAFENIB;

AGED; ARTICLE; BRAIN DISEASE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCORTICOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS;

EID: 77953409338     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-2-9133     Document Type: Article

References (14)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Lopez PM, Villanueva A, Llovet JM: Systematic review: evidence-based management of hepatocellular carcinoma an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006, 23:1535-47.
3. Abou-Alfa GK: Current and novel therapeutics of hepatocellular carcinoma. Am Soc Clin Oncol Educational Book, Alexandria, VA 2004:192-197.
4. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-8.
5. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, Wilkie D, Carter CA, Taylor IC, Lynch M, Wilhelm S: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007, 59:561-74.
6. Llovet M, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90.
7. Ratain MJ, Eisen T, Stadler WM, Flaherty KY, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 2007, 356:125-134.
9. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite P: Hypoxia-inducible factor 1 reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the in the mouse. J Am Coll Cardiol 2005, 46:2116-2124.
10. Waltenberger J: Modulation of growth factor action: Implications for the treatment of cardiovascular diseases. Circulation 1997, 96:4083-4094.
11. Parisi Q, Biondi-Zoccai GG, Abbate A, Santini D, Vasaturo F, Scarpa S, Bussani R, Leone AM, Petrolini A, Silvestri F, Biasucci LM, Baldi A: Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol 2005, 99:337-339.
12. Snow H, Brueckner A, Gelder M: Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types [abstract]. Ann Oncol 2008:abs 553.
13. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-12.
14. Tolcher A, Happleman L, Mita A: Effect of Sorafenib treatment on left ventricular ejection fraction in cancer patients: an open label, phase I study[abstract]. Ann Oncol 2008:abs 552.